Introducing VITROS® QC Solutions, taking your lab to the next level with Thermo Scientific™ MAS™ Quality Controls
Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play, in-vitro diagnostics (IVD) companies, today announced its distribution agreement with Thermo Fisher Scientific™ to provide and support MAS™ Quality Controls and Lablink xL™ Quality Assurance Software through Ortho’s VITROS® QC Solutions to VITROS® System customers worldwide.*
The VITROS QC Solutions will provide customers with a combination of Ortho Clinical Diagnostics controls and Thermo Scientific MAS Quality Controls to bring a complete quality control solution to the laboratory. Featuring consolidated, liquid-ready, Gen-Specific Value assignment along with LabLink xL, a web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. VITROS System customers will have access to the unique Gen-Specific Peer Group evaluation, that is currently unavailable through any other quality control program.
Paired with the proprietary technologies and benefits only available on VITROS Systems, VITROS QC Solutions improves workflows and drives efficiency, enabling labs to streamline operations without sacrificing quality.
“Ortho continues to bring innovative solutions to market, like our latest VITROS QC Solutions, that allow labs to take charge of their operations with improved ease of use and optimized product utilization – saving them time and money”, said Bryan Hanson, Head of Clinical Laboratories Business Unit at Ortho Clinical Diagnostics. “Through this agreement with Thermo Fisher Scientific, we can provide laboratories with better solutions, allowing them to maximize their laboratory productivity.”
More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test Is A LifeTM, Ortho provides hospitals, hospital networks, clinical laboratories, and blood banks around the globe with innovative IVD technologies to ensure test results are fast, accurate and reliable. Ortho helps its customers enhance clinical outcomes, improve efficiency, overcome staffing challenges and reduce costs.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test is a LifeTM, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.
From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing among the first high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years.
The company is powered by Ortho CareTM, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.
*China in Development